Press Release Archive
Press Releases
March 2019
03.18.2019 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due To The Presence of Particulate Matter 03.17.2019 Research AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention 03.11.2019 Medicines U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1 03.08.2019 Medicines European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma 03.05.2019 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 03.04.2019 Finance Pfizer Prices $5,000,000,000 Debt Offering 03.01.2019 Medicines Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
February 2019
02.28.2019 Research Vaccines Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older 02.19.2019 Medicines Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis 02.19.2019 Research Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials 02.19.2019 Medicines Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®* 02.19.2019 Research Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.